Pulse Biosciences, Inc.

The Company has historically financed its operations primarily through the sale of common stock and debt.

SEC original ↗Pulse Biosciences, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Expected Dividend The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock.

SEC original ↗Pulse Biosciences, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Therefore, the Company used an expected dividend yield of zero.

SEC original ↗Pulse Biosciences, Inc. — 10-Q Quarterly report10-QAug 6, 2026

The Monte Carlo simulation models require the Company to make assumptions and judgements about the variables used in the calculations including the expected volatility, the risk-free interest rate, expected dividend yield, and the expected term.

SEC original ↗Pulse Biosciences, Inc. — 10-Q Quarterly report10-QAug 6, 2026

In addition, shares remaining available under the Company s 2015 Equity Incentive Plan, as amended (the 2015 Plan ), and shares reserved but not issued pursuant to outstanding equity awards that expire or terminate without being exercised or that are forfeited or repurchased by the Company will be added to the shares of common stock available for issuance under the 2017 Plan.

SEC original ↗Pulse Biosciences, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Recent Business Highlights Endocardial Catheter AF Ablation Announced strategic prioritization of the nPulse Cardiac Catheter System following landmark clinical data, presented at AF Symposium, demonstrating exceptional procedure efficiency and durable outcomes.

SEC original ↗Pulse Biosciences, Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026

We sharpened our strategic focus on electrophysiology based on landmark clinical outcomes that reinforced the durability and efficiency of AF treatment with the nPulse catheter and commenced enrollment in our U.

SEC original ↗Pulse Biosciences, Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026

Liane Teplitsky joined Pulse Biosciences as Chief Operating Officer and brings a wealth of experience in electrophysiology at this consequential moment of our strategic focus.

SEC original ↗Pulse Biosciences, Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026

Failure to raise sufficient capital when needed or generate sufficient cash flow from operations would impact the ability to pursue business strategies and could require the Company to delay, scale back or discontinue one or more product development programs, or other aspects of the Company s business objectives.

SEC original ↗Pulse Biosciences, Inc. — 10-Q Quarterly report10-QAug 6, 2026

As a basis for considering such assumptions, a three -tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: Level 1 Observable inputs, such as quoted prices in active markets for identical assets or liabilities at the measurement date.

SEC original ↗Pulse Biosciences, Inc. — 10-Q Quarterly report10-QAug 6, 2026

You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences control.

SEC original ↗Pulse Biosciences, Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026

Legal Proceedings 33 Item 1A.

SEC original ↗Pulse Biosciences, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company s research efforts and any related patent applications, patent costs not related to acquired patents, including patent-related legal fees, filing fees and other costs, including internally generated costs, are expensed as incurred.

SEC original ↗Pulse Biosciences, Inc. — 10-Q Quarterly report10-QAug 6, 2026

The analysis to determine such probability involves estimates and judgements from management related to certain financial measures and achievements of strategic and operational milestones, which involve inherent risk and uncertainty regarding the future outcomes of the milestones.

SEC original ↗Pulse Biosciences, Inc. — 10-Q Quarterly report10-QAug 6, 2026